Article
Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.
Cancer research - 15 Aug 2007
Ogino Atsuko, Kitao Hiroyuki, Hirano Seiki, Uchida Akiko, Ishiai Masamichi, Kozuki Toshiyuki, Takigawa Nagio, Takata Minoru, Kiura Katsuyuki, Tanimoto Mitsune
Abstract excerpt
The epidermal growth factor receptor (EGFR)-specific tyrosine kinase inhibitor gefitinib may provide dramatic clinical responses in some patients with pulmonary adenocarcinoma carrying activating mutations of the EGFR. However, prolonged administration of gefitinib may eventually induce acquired resistance in such patients. To gain insight into the mechanisms of this phenomenon, we placed PC-9, a cell line...
Topics
- Adenocarcinoma
- Carcinoma, Non-Small-Cell Lung
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- ErbB Receptors
- Gefitinib
- Humans
- Lung Neoplasms
- Mutation
- Phosphorylation